• Raghavendra Kotal, Ipe Jacob, Pradeep Rangappa, Karthik Rao, Guruprasad Hosurkar, Satish Kumar Anumula, and Avinasha M Kuberappa.
• Department of Intensive Care, Columbia Asia Hospital, Bengaluru, Karnataka, India.
• Surg Neurol Int. 2021 Jan 1; 12: 408.

BackgroundThe use of the COVID-19 vaccines Vaxzevria from AstraZeneca and Covishield from Janssen has been associated with sporadic reports of thrombosis with thrombocytopenia, a complication referred to as vaccine-induced immune thrombotic thrombocytopenia (VITT) or vaccine-induced prothrombotic immune thrombocytopenia. It presents commonly as cerebral sinus venous thrombosis (CSVT), within 4-30 days of vaccination. Females under 55 years of age are considered to be especially at high risk. Mortality up to 50% has been reported in some countries. Identification of early warning signs and symptoms with prompt medical intervention is crucial.Case DescriptionWe report here a case of VITT in a young female who presented 11 days after receiving the first dose of the Covishield vaccine, with severe headache and hemiparesis. She was diagnosed with CSVT with a large intraparenchymal bleed, requiring decompressive craniectomy and extended period on mechanical ventilation.ConclusionThe patient was successfully treated with intravenous immunoglobulin and discharged after 19 days in ICU. Although she was left with long-term neurological deficits, an early presentation and a multidisciplinary approach to management contributed toward a relatively short stay in hospital and avoided mortality.Copyright: © 2021 Surgical Neurology International.

1 keywords...

hide…